Spectrum of PD-1 and PD-L1 inhibitor cutaneous adverse events in skin of color: a retrospective, single-institutional study in an urban community.

The article presents a study of cutaneous adverse events associated with programmed death-1 (PD-1) and PD-ligand 1 (PD-L1) inhibitor therapy in people of color (POC) and ethnically white patients. Topics discussed include the emergence of eczematous dermatitis as the most common cutaneous adverse event, reason behind the large number of POC patients with cutaneous adverse events compared with white patients, and lack of correlation between inhibitor treatment and adverse events.